Article
Immunology
Ana Carolina Matias Dinelly Pinto, Rodolfo de Melo Nunes, Igor Albuquerque Nogueira, Bernhard Fischer, Rudolf Lucas, Virginia Claudia Carneiro Girao-Carmona, Vivian Louise Soares de Oliveira, Flavio Almeida Amaral, Georg Schett, Francisco Airton Castro Rocha
Summary: TNF inhibitors are commonly used for the treatment of arthropathies like rheumatoid arthritis (RA), but not all patients achieve remission and there is a risk of infection. This study found that the lectin-like domain of TNF has anti-inflammatory effects and can mitigate the development of immune-mediated arthritis in mice.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Paolo Gisondi, Francesco Bellinato, Giovanni Targher, Luca Idolazzi, Giampiero Girolomoni
Summary: In patients with moderate-to-severe chronic plaque psoriasis, treatment with bDMARDs may delay or reduce the risk of incident PsA. The annual incidence rate of PsA was significantly lower in the bDMARDs group compared to the phototherapy group. Factors associated with a higher risk of PsA included older age, nail psoriasis, and psoriasis duration over 10 years.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Medicine, General & Internal
Pierluigi Macchioni, Antonio Marchesoni, Giovanni Ciancio, Gilda Sandri, Alen Zabotti, Gentiana Vukatana, Luca Montaguti, Mariacristina Focherini, Marcello Govoni, Amelia Spinella, Nazzarena Malavolta, Francesca Zuliani, Marco Bruschi, Fabio Mascella, Carlo Salvarani
Summary: In this multicenter study, Psoriatic arthritis (PsA) patients in a stable state of Minimal Disease Activity (MDA) were examined using ultrasound (US). The results showed that PsA patients in MDA may still have residual inflammation in peripheral articular structures.
FRONTIERS IN MEDICINE
(2022)
Review
Immunology
Anais Makos, J. H. Kuiper, O. Kehoe, R. Amarasena
Summary: Psoriatic arthritis is a chronic and painful inflammatory immune-mediated disease. This study aimed to identify potential biomarkers for predicting treatment response and guiding biologic drug therapy.
INFLAMMOPHARMACOLOGY
(2023)
Review
Endocrinology & Metabolism
Chrong-Reen Wang, Hung-Wen Tsai
Summary: Insulin resistance (IR) is a crucial mechanism leading to the development of diabetes mellitus (DM), requiring higher than normal insulin concentrations to maintain euglycemic status. Many human inflammatory disorders, particularly autoimmune-mediated arthritis conditions, have been associated with an increased risk of IR, especially during active disease states. Using biologic agents and small molecule-targeted drugs can reduce IR and improve diabetic hyperglycemia in autoimmune-mediated arthritis.
WORLD JOURNAL OF DIABETES
(2021)
Article
Rheumatology
Vincenzo Venerito, Pasquale Stefanizzi, Marco Fornaro, Fabio Cacciapaglia, Silvio Tafuri, Simone Perniola, Florenzo Iannone, Giuseppe Lopalco
Summary: This study investigated the humoral response to BNT162b2 vaccination in patients with PsA on TNFi treatment and compared it with healthy controls. The study found that continuing TNFi treatment did not hinder the immunogenicity of the vaccine.
Article
Rheumatology
Siri Lillegraven, Nina Paulshus Sundlisaeter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Ase Stavland Lexberg, Tor Magne Madland, Hallvard Fremstad, Christian A. Hoili, Gunnstein Bakland, Cristina Spada, Hilde Haukeland, Inger Myrnes Hansen, Ellen Moholt, Till Uhlig, Daniel H. Solomon, Desiree Van der Heijde, Tore K. Kvien, Espen A. Haavardsholm
Summary: This study aimed to assess the effect of tapering tumor necrosis factor inhibitor (TNFi) to withdrawal compared with stable treatment on the risk of disease activity flares in patients with rheumatoid arthritis (RA) in remission for more than 1 year. The results showed that in the tapering TNFi group, 63% experienced a flare during 12 months, compared to 5% in the stable TNFi group. Therefore, tapering TNFi to discontinuation is not non-inferior to continued stable treatment.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Celia A. J. Michielsens, Nathan den Broeder, Frank H. J. van den Hoogen, Elien A. M. Mahler, Steven Teerenstra, Desiree van der Heijde, Lise M. Verhoef, Alfons A. den Broeder
Summary: In patients with PsA and axSpA, a T2T TNFi strategy with tapering attempt is non-inferior to a T2T strategy without tapering in terms of the proportion of patients still in low disease activity (LDA) at 12 months, and results in a substantial reduction of TNFi use.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibanez, Tatiana Korotaeva, Frederic Lavie, Wim Noel, Michael T. Nurmohamed, Petros P. Sfikakis, Mohamed Sharaf, Elke Theander, Josef S. Smolen
Summary: This study evaluated the real-world persistence and effectiveness of the IL-12/23 inhibitor ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years. The results showed that the proportion of patients still on their initial treatments after 3 years was similar with ustekinumab and TNFi, but ustekinumab had a lower rate of adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibanez, Tatiana Korotaeva, Frederic Lavie, Wim Noel, Michael T. Nurmohamed, Petros P. Sfikakis, Elke Theander, Josef S. Smolen
Summary: In the real-world treatment of psoriatic arthritis, ustekinumab and TNFi demonstrate comparable overall treatment persistence, effectiveness, and safety.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Iain B. McInnes, Koji Kato, Marina Magrey, Joseph F. Merola, Mitsumasa Kishimoto, Cesar Pacheco-Tena, Derek Haaland, Liang Chen, Yuanyuan Duan, Patrick Zueger, John Liu, Ralph Lippe, Aileen L. Pangan, Franck Behrens
Summary: Upadacitinib demonstrated superior efficacy in PsA patients compared to adalimumab and placebo, with sustained improvement seen through 56 weeks and favorable safety profile.
Article
Rheumatology
Alejandro Ibanez-Costa, Carlos Perez-Sanchez, Alejandra Maria Patino-Trives, Maria Luque-Tevar, Pilar Font, Ivan Arias de la Rosa, Cristobal Roman-Rodriguez, Ma Carmen Abalos-Aguilera, Carmen Conde, Antonio Gonzalez, Sergio Pedraza-Arevalo, Mercedes del Rio-Moreno, Ricardo Blazquez-Encinas, Pedro Segui, Jerusalem Calvo, Rafaela Ortega Castro, Alejandro Escudero-Contreras, Nuria Barbarroja, Ma Angeles Aguirre, Justo P. Castano-Fuentes, Raul M. Luque, Eduardo Collantes-Estevez, Chary Lopez-Pedrera
Summary: This study identified altered expression of several splicing machinery elements in leucocytes of rheumatoid arthritis patients, with 8 elements equally affected in all leucocyte subtypes. These alterations could discriminate patients from healthy donors, classify high disease activity, recognize radiological involvement, and identify patients with atheroma plaques. The signature was also found in RA synovial fluid and ankle joints of arthritic mice, and could be reversed by anti-TNF therapy.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Philip S. Helliwell, Phillip J. Mease, Arthurl Kavanaugh, Laura C. Coates, Alexis Ogdie, Atul Deodhar, Vibeke Strand, Gregory Kricorian, Lyrica X. H. Liu, David Collier, Dafna D. Gladman
Summary: The presence of dactylitis and nail disease is associated with improved outcomes in patients with early PsA who were treated with methotrexate and/or etanercept, while enthesitis is not.
Article
Rheumatology
Sibel Bakirci, Gizem Ayan, Ummugulsum Gazel, Ilaria Tinazzi, Dilek Solmaz, Esen Kasapoglu, Umut Kalyoncu, Sibel Zehra Aydin
Summary: The study found that PsA patients show differences in patient characteristics, disease phenotypes, treatment approaches, and MDA rates across different countries. These variations may be attributed to a combination of genetic, geographical, or demographic factors in specific regions. Therefore, the unmet needs of PsA patients may vary globally.
CLINICAL RHEUMATOLOGY
(2021)
Article
Rheumatology
Yu-Jih Su, Hui-Ming Chen, Tien-Ming Chan, Tien-Tsai Cheng, Shan-Fu Yu, Jia-Feng Chen, Chun-Yu Lin, Chung-Yuan Hsu
Summary: This study aimed to investigate whether patients using disease-modifying anti-rheumatic drugs (DMARDs) may have different levels of risk for diabetes and to analyze other risk factors for diabetes. The results showed that certain DMARDs can reduce the risk of diabetes.
Article
Rheumatology
Laura C. Coates, Ennio Lubrano, Fabio Massimo Perrotta, Paul Emery, Philip G. Conaghan, Philip S. Helliwell
JOURNAL OF RHEUMATOLOGY
(2019)
Article
Rheumatology
Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta
JOURNAL OF RHEUMATOLOGY
(2020)
Article
Immunology
Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2020)
Article
Rheumatology
Ennio Lubrano, Silvia Scriffignano, Romeo Morelli, Fabio Massimo Perrotta
Summary: The study found that FM patients had significantly higher numbers of pain areas and WPI scores compared to PsA patients. The number of reported body areas in PsA correlated with disease activity, function, and impact of disease. Widespread and extraarticular pain was present in PsA patients.
JOURNAL OF RHEUMATOLOGY
(2021)
Article
Rheumatology
Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta
Summary: The study focused on Minimal Disease Activity (MDA) in psoriatic arthritis, analyzing its division into seven cutoffs and the relationship with other measures. It found that physician-driven domains were more frequently achieved in patients not meeting MDA criteria, indicating potential areas for improvement in treatment strategies.
RHEUMATOLOGY AND THERAPY
(2021)
Article
Rheumatology
Fabio Massimo Perrotta, Silvia Scriffignano, Ennio Lubrano
Summary: Our study revealed extra-axial abnormalities in more than one-third of patients with axial SpA, suggesting that MRI evaluation should be extended to the entire pelvis.
RHEUMATOLOGY AND THERAPY
(2021)
Article
Medicine, General & Internal
Antonio Marchesoni, Pierluigi Macchioni, Stefania Gasparini, Carlo Perricone, Fabio Massimo Perrotta, Rosa Daniela Grembiale, Ettore Silvagni, Roberta Ramonda, Luisa Costa, Alen Zabotti, Giacomo Curradi, Giuliana Gualberti, Francesca Marando, Carlo Salvarani
Summary: This study evaluated the use of ultrasound examination to distinguish pain from enthesitis in patients with psoriatic arthritis (PsA) and fibromyalgia syndrome (FMS). The results showed that PsA patients had a higher percentage of entheseal changes compared to FMS patients. The ultrasound evaluation can be helpful in differentiating the cause of pain in these patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Rheumatology
Fabio Massimo Perrotta, Silvia Scriffignano, Francesco Ciccia, Ennio Lubrano
Summary: This study aimed to characterize potential difficult-to-treat (D2T) patients with psoriatic arthritis (PsA). The results showed that D2T patients had significantly higher BMI, higher prevalence of fibromyalgia, higher comorbidity indices, disease activity, and delayed time from diagnosis to treatment compared to non-D2T patients.
RHEUMATOLOGY AND THERAPY
(2022)
Editorial Material
Rheumatology
Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta
RHEUMATOLOGY AND THERAPY
(2023)
Article
Rheumatology
Ennio Lubrano, Silvia Scriffignano, Mauro Fatica, Paola Triggianese, Paola Conigliaro, Fabio Massimo Perrotta, Maria Sole Chimenti
Summary: The study aimed to evaluate the differences and similarities in psoriatic arthritis (PsA) between sexes, as well as to assess the potential impact of psoriasis on disease burden in PsA patients. The results showed that female PsA patients had a higher disease severity, greater disease activity, worse function, and higher disease burden, while males were more prone to skin involvement. However, there was no significant association between skin involvement and patient global assessment in the regression analysis.
RHEUMATOLOGY AND THERAPY
(2023)
Article
Rheumatology
Silvia Scriffignano, Fabio Massimo Perrotta, Paola Conigliaro, Mario Ferraioli, Paola Triggianese, Maria Sole Chimenti, Ennio Lubrano
Summary: The aim of this study was to determine the main MDA domains achieved in PsA patients based on different treatments. Patient global assessment and pain were found to be the least frequently achieved MDA domains, indicating an unmet need for patient-driven outcomes. Larger and prospective studies are needed to confirm these preliminary results and advance personalized treatment approaches in PsA.
RHEUMATOLOGY AND THERAPY
(2023)
Editorial Material
Rheumatology
Ennio Lubrano, Silvia Scriffignano, Fabio Massimo Perrotta
Summary: Psoriatic arthritis (PsA) is a complex and chronic inflammatory disease, and achieving the best disease control is the treatment target. However, some patients may still have high disease activity and burden, leading to treatment changes and management difficulties. This paper provides an overview of difficult-to-treat and refractory-to-treatment PsA, distinguishing between these concepts and discussing implications for patient management.
RHEUMATOLOGY AND THERAPY
(2023)
Review
Respiratory System
Fabio Perrotta, Vittorio Chino, Valentino Allocca, Vito D'Agnano, Chandra Bortolotto, Andrea Bianco, Angelo Guido Corsico, Giulia Maria Stella
Summary: This article aims to provide knowledge about IPF and cancer patients from a multidisciplinary perspective, which represents an unmet clinical need. Better management during each phase of disease progression will require the design of innovative trials and the development of new drugs in both oncology and respiratory medicine.
EXPERT REVIEW OF RESPIRATORY MEDICINE
(2022)
Article
Rheumatology
F. M. Perrotta, S. Scriffignano, M. Fatica, M. Specchia, E. Lubrano
Article
Rheumatology
F. M. Perrotta, S. Scriffignano, A. De Socio, E. Lubrano
